Ascione Guido, Del Forno Benedetto, Carino Davide, Lapenna Elisabetta, Schiavi Davide, Denti Paolo, Bisogno Arturo, Verzini Alessandro, Iaci Giuseppe, Alfieri Ottavio, Castiglioni Alessandro, De Bonis Michele
Department of Cardiac Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alfieri Heart Foundation, Milan, Italy.
Fac Rev. 2020 Dec 21;9:26. doi: 10.12703/r/9-26. eCollection 2020.
Tricuspid valve regurgitation is an insidious pathology that is associated with increased mortality if left untreated. Conversely, surgical correction of tricuspid regurgitation is burdened by poor outcomes, especially when right ventricular dysfunction, kidney disease, or liver disease occur. There is, therefore, increasing interest in transcatheter approaches as an alternative to surgery in patients at high or prohibitive surgical risk. The development of percutaneous devices to treat tricuspid regurgitation has several technical challenges, mainly because of the complexity of valve anatomy, thus requiring accurate patient selection. Here we review the currently available transcatheter approaches to treat severe tricuspid regurgitation.
三尖瓣反流是一种隐匿性病变,如果不治疗,会导致死亡率增加。相反,三尖瓣反流的外科矫正效果不佳,尤其是在出现右心室功能障碍、肾脏疾病或肝脏疾病时。因此,对于手术风险高或无法进行手术的患者,经导管治疗方法作为手术替代方案的关注度日益增加。开发用于治疗三尖瓣反流的经皮装置存在若干技术挑战,主要是因为瓣膜解剖结构复杂,因此需要准确选择患者。在此,我们综述目前可用的治疗严重三尖瓣反流的经导管方法。